Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jungryun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Korea University, Seoul 02841, Korea. Hauptthemen laut MEDLINE: Prodrugs, Dexamethasone, Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Research Foundation of Korea, Natural Science Basic Research Program of Shaanxi Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Residual tumor cells that persist after chemotherapy, even in minimal quantities, often exhibit drug resistance and increased invasiveness, potentially leading to tumor metastasis and recurrence. This study introduces a novel reactive oxygen species (ROS)-responsive prodrug, Dex-Dox, designed to overcome multidrug resistance (MDR) in tumor cells. The prodrug is composed of the anti-inflammatory glucocorticoid dexamethasone (Dex) conjugated with doxorubicin (Dox), a widely used antitumor agent, through an oxidative stress-responsive linker. Our in vitro findings revealed that, while Dex alone did not exhibit antitumor activity, Dex-Dox significantly enhanced drug sensitivity, promoting apoptosis and inhibiting angiogenesis in drug-resistant cells. Furthermore, in vivo therapeutic evaluations and histological analyses demonstrated that Dex-Dox substantially reduced tumor volumes, especially in a Dox-resistant tumor mouse model, underscoring its potential as an effective strategy against MDR in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Korea University, Seoul 02841, Korea.
- Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China.
- Institute of Medical Engineering, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.
ORCID-Profile: Paramesh Jangili, Fu Wang, Jong Seung Kim
Förderung
- National Research Foundation of Korea
- Natural Science Basic Research Program of Shaanxi Province
- National Natural Science Foundation of China
Zitieren
APA
Kim, J., Hu, C., Jangili, P., Tang, C., Wang, F., & Kim, J. S. (2025). Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02565
Vancouver
Kim J, Hu C, Jangili P, Tang C, Wang F, Kim JS. Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02565
BibTeX
@article{Kim2025,
author = {Kim, Jungryun and Hu, Chong and Jangili, Paramesh and Tang, Chu and Wang, Fu and Kim, Jong Seung},
title = {Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02565}
}
EUVIMED